Valuation: Mendus AB

Market Cap 344M 34.79M 31.01M 28.71M 25.98M 48.94M 3.28B 49.52M 135M 1.73B 131M 128M 5.5B P/E 2026 *
-3.41x
P/E 2027 * -5.18x
Enterprise Value 365M 36.95M 32.92M 30.48M 27.59M 51.97M 3.49B 52.59M 143M 1.83B 139M 136M 5.84B EV / Sales 2026 *
47.9x
EV / Sales 2027 * 1x
Free-Float
35.25%
Yield 2026 *
-
Yield 2027 * -
1 week+2.15%
Current month-17.67%
1 month-22.55%
3 months-19.69%
6 months+6.21%
Current year-6.79%
1 week 4.9
Extreme 4.9
5.45
1 month 4.9
Extreme 4.9
6.77
Current year 3.86
Extreme 3.86
8.49
1 year 3.86
Extreme 3.86
8.49
3 years 3.86
Extreme 3.86
16.38
5 years 3.86
Extreme 3.86
126.8
10 years 3.86
Extreme 3.86
640
Manager TitleAgeSince
Chief Executive Officer 76 2019-12-12
Chief Executive Officer 54 2021-03-15
Director of Finance/CFO 60 2021-02-27
Director TitleAgeSince
Chairman 52 2021-01-21
Director/Board Member 64 2019-12-31
Director/Board Member 74 2012-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
2/28/22 Buy

Chief Technology Officer

10,000 0.0050%
2/24/22 Buy

Chief Financial Officer

10,000 0.0050%
2/24/22 Buy

Chief Financial Officer

10,000 0.0050%
Change 5-day change 1-year change 3-year change Capi.($)
+0.10%+2.15%-6.62%-33.42% 34.79M
-0.21%-4.43%+44.40%+74.13% 66.22B
-1.73%+1.90%+9.00%+71.43% 55.2B
+0.26%+3.44%+11.54%+90.66% 52.79B
+3.28%+5.58%+26.51%+50.05% 45.53B
+0.51%+9.95%+22.40%+133.92% 43.94B
-1.15%+0.39%+263.21%+594.60% 41.64B
+0.10%+9.90%+16.11%+59.33% 34B
-8.38%-6.95%+26.35%-1.93% 25.84B
+0.65%+4.07%+37.08%+26.97% 23.51B
Average -0.67%+3.19%+45.00%+106.57% 38.87B
Weighted average by Cap. -0.44%+3.72%+49.65%+126.48%

Financials

2026 *2027 *
Net sales 7.63M 772K 688K 637K 576K 1.09M 72.82M 1.1M 3M 38.28M 2.89M 2.83M 122M 172M 17.41M 15.51M 14.36M 12.99M 24.48M 1.64B 24.77M 67.55M 863M 65.29M 63.93M 2.75B
Net income -99.17M -10.03M -8.93M -8.27M -7.49M -14.1M -946M -14.27M -38.91M -497M -37.61M -36.83M -1.58B -33.34M -3.37M -3M -2.78M -2.52M -4.74M -318M -4.8M -13.08M -167M -12.64M -12.38M -533M
Net Debt 21.31M 2.15M 1.92M 1.78M 1.61M 3.03M 203M 3.07M 8.36M 107M 8.08M 7.91M 341M -172M -17.39M -15.5M -14.35M -12.98M -24.46M -1.64B -24.75M -67.49M -863M -65.23M -63.87M -2.75B
Projected Income Statement - Annual - Mendus AB
Logo Mendus AB
Mendus AB (publ), formerly Immunicum AB, is a Sweden-based company that is engaged in the biopharmaceutical sector. The Company develops immunotherapy for therapeutic treatment of cancer and infectious diseases. The Company develops off-the-shelf, cell-based products that are immunogenic based on underlying allogeneic dendritic cell biology and which have the potential to activate the patient’s own immune system against cancer. The Company’s programs ilixadencel and DCP-001 are derived from healthy donor material and from Company's DCOne cell line, respectively. The Company develops ilixadencel to address the tumor burden of established tumors via intratumoral immune priming and DCP-001 as a cancer relapse vaccine, aimed at the reduction of tumor recurrence following initial treatment. Mendus has offices in Sweden and the Netherlands.
Employees
19
Date Price Change Volume
26-10-22 SEK 5.220 +0.58% 700
26-10-21 SEK 5.190 +1.37% 27,596
26-10-20 SEK 5.120 -1.54% 29,251
26-10-19 SEK 5.200 -3.70% 31,042
26-10-16 SEK 5.400 +5.68% 16,035
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Mendus AB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
5.190SEK
Average target price
33.95SEK
Spread / Average Target
+554.14%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Mendus AB
  1. Stock Market
  2. Stocks
  3. IMMU Stock